英夫利西单抗联合治疗中毒性表皮坏死松解症4例

doi:10.35541/cjd.20220887

Chinese Journal of Dermatology ›› 2024, e20220887.doi: 10.35541/cjd.20220887

• Case Reports • Previous Articles Next Articles

Infliximab for the treatment of 4 cases of toxic epidermal necrolysis

Wang Wenming, Shu Chang, He Chunxia, Song Hongbin, Wu Mengyin, Jin Hongzhong

Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Clinical Research Center for Skin and Immune Diseases, Beijing 100730, China

Received:2022-12-09 Revised:2023-10-20 Online:2024-01-05 Published:2024-08-19
Contact: Jin Hongzhong E-mail:jinhongzhong@263.net
Supported by:
National High-level Hospital Clinical Research Funding （2022-PUMCH-A-251）; National Natural Science Foundation of China （82073450）; National Key R&D Program of China （2022YFC3601800）

Abstract

Wang Wenming, Shu Chang, He Chunxia, Song Hongbin, Wu Mengyin, Jin Hongzhong. Infliximab for the treatment of 4 cases of toxic epidermal necrolysis[J]. Chinese Journal of Dermatology,2024,e20220887. doi:10.35541/cjd.20220887

References ［10］

［1］	中华医学会皮肤性病学分会药物不良反应研究中心. Stevens⁃Johnson综合征/中毒性表皮坏死松解症诊疗专家共识［J］. 中华皮肤科杂志, 2021,54（5）:376⁃381. doi: 10.35541/cjd.20201177.
［2］	Wang CW, Yang LY, Chen CB, et al. Randomized, controlled trial of TNF⁃α antagonist in CTL⁃mediated severe cutaneous adverse reactions［J］. J Clin Invest, 2018,128（3）:985⁃996. doi: 10.1172/JCI93349.
［3］	Hasegawa A, Abe R. Recent advances in managing and understanding Stevens⁃Johnson syndrome and toxic epidermal necrolysis［J］. F1000Res, 2020,9:612. doi: 10.12688/f1000research. 24748.1.
［4］	Barron SJ, Del Vecchio MT, Aronoff SC. Intravenous immunoglobulin in the treatment of Stevens⁃Johnson syndrome and toxic epidermal necrolysis: a meta⁃analysis with meta⁃regression of observational studies［J］. Int J Dermatol, 2015,54（1）:108⁃115. doi: 10.1111/ijd.12423.
［5］	Hunger RE, Hunziker T, Buettiker U, et al. Rapid resolution of toxic epidermal necrolysis with anti⁃TNF⁃alpha treatment［J］. J Allergy Clin Immunol, 2005,116（4）:923⁃924. doi: 10.1016/j.jaci.2005.06.029.
［6］	Paradisi A, Abeni D, Bergamo F, et al. Etanercept therapy for toxic epidermal necrolysis［J］. J Am Acad Dermatol, 2014,71（2）:278⁃283. doi: 10.1016/j.jaad.2014.04.044.
［7］	Pham CH, Gillenwater TJ, Nagengast E, et al. Combination therapy: etanercept and intravenous immunoglobulin for the acute treatment of Stevens⁃Johnson syndrome/toxic epidermal necrolysis［J］. Burns, 2019,45（7）:1634⁃1638. doi: 10.1016/j.burns.2018.12.018.
［8］	Gaitanis G, Spyridonos P, Patmanidis K, et al. Treatment of toxic epidermal necrolysis with the combination of infliximab and high⁃dose intravenous immunoglobulin［J］. Dermatology, 2012,224（2）:134⁃139. doi: 10.1159/000338202.
［9］	Zárate⁃Correa LC, Carrillo⁃Gómez DC, Ramírez⁃Escobar AF, et al. Toxic epidermal necrolysis successfully treated with infliximab［J］. J Investig Allergol Clin Immunol, 2013,23（1）:61⁃63.
［10］	Chafranska L, Saunte DM, Behrendt N, et al. Pediatric toxic epidermal necrolysis treated successfully with infliximab［J］. Pediatr Dermatol, 2019,36（3）:342⁃345. doi: 10.1111/pde.13778.

Infliximab for the treatment of 4 cases of toxic epidermal necrolysis

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［10］

Related Articles 0

Metrics

Comments

Recommended 10